Lantern Pharma Reports Positive Phase 1a Data For LP-184 In Advanced Solid Tumors
Lantern Pharma Inc. reported positive results from its Phase 1a study of LP-184 in advanced solid tumors, showing durable disease control in patients with DDR pathway deficiencies. The study met safety and tolerability endpoints, and Lantern plans to advance LP-184 into Phase 1b/2 trials.
Add 
as your preferred news source on Google
Add Now
Lantern Pharma Inc. (LTRN), a clinical-stage biotechnology company, on Wednesday shared additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184.
The trial showed encouraging, durable disease control in heavily pre-treated patients with advanced solid tumors, many of whom had DNA damage repair (DDR) pathway deficiencies. The study met all primary endpoints for safety and tolerability.
Lantern said it plans to advance LP-184 into multiple Phase 1b/2 trials.
For comments and feedback contact: editorial@rttnews.com
Business News
